{"id":"W2140868856","doi":"10.1056/nejmoa1105185","title":"A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":2174,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children; University of Toronto; St. Michael's Hospital","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; Children's Hospital of Pittsburgh; University of Alabama; National Center for Research Resources; University of Pennsylvania; Seattle Children's Research Institute; Vertex Pharmaceuticals; Case Western Reserve University; Medical Center, University of Pittsburgh; Cystic Fibrosis Foundation; University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases; Johns Hopkins University; Imperial College London; University of Washington; Cystic Fibrosis Foundation Therapeutics; National Institute for Health and Care Research; University of Alabama at Birmingham; Children's Hospital of Philadelphia","keywords":"Potentiator; Cystic fibrosis; Medicine; Ivacaftor; Cystic fibrosis transmembrane conductance regulator; Mutation; Internal medicine; Genetics; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009679022501706713,"score_gpt":0.2428851548663161,"score_spread":0.2332061323646094,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}